1文献来源研究一:Hellmann MD,Ciuleanu TE,Pluzanski A,et al.Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden[J].N Engl J Med,2018,378(22):2093-2104.研究二:Hellmann MD,Paz-Ares L,Bernabe Caro ...1文献来源研究一:Hellmann MD,Ciuleanu TE,Pluzanski A,et al.Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden[J].N Engl J Med,2018,378(22):2093-2104.研究二:Hellmann MD,Paz-Ares L,Bernabe Caro R,et al.Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer[J].N Engl J Med,2019,381(21):2020-2031.2证据水平1b。3背景纳武利尤单抗联合伊匹木单抗治疗非小细胞肺癌(non-small-cell lung cancer,NSCLC)在Ⅰ期临床试验中获得很好疗效,肿瘤突变负荷(tumour mutation burden,TMB)是潜在的生物标志物,但仍需Ⅲ期临床试验来探索在TMB高(≥10个突变/Mb)的人群中双免疫治疗对比含铂双药化疗的无进展生存期(progression-free survival,PFS)。展开更多
文摘1文献来源研究一:Hellmann MD,Ciuleanu TE,Pluzanski A,et al.Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden[J].N Engl J Med,2018,378(22):2093-2104.研究二:Hellmann MD,Paz-Ares L,Bernabe Caro R,et al.Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer[J].N Engl J Med,2019,381(21):2020-2031.2证据水平1b。3背景纳武利尤单抗联合伊匹木单抗治疗非小细胞肺癌(non-small-cell lung cancer,NSCLC)在Ⅰ期临床试验中获得很好疗效,肿瘤突变负荷(tumour mutation burden,TMB)是潜在的生物标志物,但仍需Ⅲ期临床试验来探索在TMB高(≥10个突变/Mb)的人群中双免疫治疗对比含铂双药化疗的无进展生存期(progression-free survival,PFS)。
